These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 7344452)

  • 21. The effect of hepatic metabolism on the production and toxicity of reactive metabolites in extrahepatic organs.
    Boyd MR; Statham CN
    Drug Metab Rev; 1983; 14(1):35-47. PubMed ID: 6839941
    [No Abstract]   [Full Text] [Related]  

  • 22. Dose dependent conversion of estragole in the rat and mouse to the carcinogenic metabolite, 1'-hydroxyestragole.
    Zangouras A; Caldwell J; Hutt AJ; Smith RL
    Biochem Pharmacol; 1981 Jun; 30(11):1383-6. PubMed ID: 7271835
    [No Abstract]   [Full Text] [Related]  

  • 23. [Biotransformation of drugs by the liver].
    González Macias JG
    Rev Clin Esp; 1974 Nov; 135(3):207-18. PubMed ID: 4615350
    [No Abstract]   [Full Text] [Related]  

  • 24. 32P-post-labelling analysis of DNA adducts formed in the livers of animals treated with safrole, estragole and other naturally-occurring alkenylbenzenes. I. Adult female CD-1 mice.
    Randerath K; Haglund RE; Phillips DH; Reddy MV
    Carcinogenesis; 1984 Dec; 5(12):1613-22. PubMed ID: 6499112
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Covalent binding of electrophilic metabolites to macromolecules.
    Pohl LR; Branchflower RV
    Methods Enzymol; 1981; 77():43-50. PubMed ID: 6173572
    [No Abstract]   [Full Text] [Related]  

  • 26. [Interaction between chemical carcinogens and nucleic acids; basis of carcinogenesis].
    Nagata C
    Tanpakushitsu Kakusan Koso; 1970 Jul; 15(8):826-41. PubMed ID: 4913735
    [No Abstract]   [Full Text] [Related]  

  • 27. Xenobiotic metabolism and toxicity in primary monolayer cultures of hepatocytes.
    Holme JA
    NIPH Ann; 1985 Dec; 8(2):49-63. PubMed ID: 3908998
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Selectivity of alkylation and aralkylation of nucleic acid components.
    Dipple A; Moschel RC; Hudgins WR
    Drug Metab Rev; 1982; 13(2):249-68. PubMed ID: 6178574
    [No Abstract]   [Full Text] [Related]  

  • 29. Mechanisms of action of N-nitroso compounds.
    Archer MC
    Cancer Surv; 1989; 8(2):241-50. PubMed ID: 2696579
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The effect of hepatic blood flow on formation of metabolites.
    Pang KS; Mulder GJ
    Drug Metab Dispos; 1990; 18(3):270-5. PubMed ID: 1974185
    [No Abstract]   [Full Text] [Related]  

  • 31. Kinetics of decomposition of chemically unstable metabolites in the presence of nucleophiles: derivation of equations used in graphical analyses.
    Gillette JR
    Pharmacology; 1980; 20(2):64-86. PubMed ID: 7384191
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Soft drugs: principles and methods for the design of safe drugs.
    Bodor N
    Med Res Rev; 1984; 4(4):449-69. PubMed ID: 6387331
    [No Abstract]   [Full Text] [Related]  

  • 33. Biosynthesis of drug metabolites and quantitation using NMR spectroscopy for use in pharmacologic and drug metabolism studies.
    Walker GS; Bauman JN; Ryder TF; Smith EB; Spracklin DK; Obach RS
    Drug Metab Dispos; 2014 Oct; 42(10):1627-39. PubMed ID: 25053618
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [Drug-induced hepatits: the role of unstable metabolites (author's transl)].
    Pessayre D; Benhamou JP
    Acta Gastroenterol Belg; 1978; 41(9-10):574-86. PubMed ID: 735686
    [No Abstract]   [Full Text] [Related]  

  • 35. Major role of hepatic sulfotransferase activity in the metabolic activation, DNA adduct formation, and carcinogenicity of 1'-hydroxy-2',3'-dehydroestragole in infant male C57BL/6J x C3H/HeJ F1 mice.
    Fennell TR; Wiseman RW; Miller JA; Miller EC
    Cancer Res; 1985 Nov; 45(11 Pt 1):5310-20. PubMed ID: 3863702
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiple drug metabolism in hepatic subcellular fractions.
    Muakkassah SF; Lowery GL; Bidlack WR
    Proc West Pharmacol Soc; 1979; 22():119-24. PubMed ID: 515040
    [No Abstract]   [Full Text] [Related]  

  • 37. Cytochrome P-450: the Japanese connection.
    Gelboin HV
    Jpn J Cancer Res; 1993 Feb; 84(2):inside front cover. PubMed ID: 8463126
    [No Abstract]   [Full Text] [Related]  

  • 38. Prediction of in vivo potential for metabolic activation of drugs into chemically reactive intermediate: correlation of in vitro and in vivo generation of reactive intermediates and in vitro glutathione conjugate formation in rats and humans.
    Masubuchi N; Makino C; Murayama N
    Chem Res Toxicol; 2007 Mar; 20(3):455-64. PubMed ID: 17309281
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A new series of review articles on drug metabolizing enzymes: nomenclature of isoenzyme families, genetic organization, polymorphisms, substrate specificities, clinical relevance and role in carcinogenesis.
    Bolt HM; Hengstler JG
    Arch Toxicol; 2008 Jul; 82(7):413-4. PubMed ID: 18528684
    [No Abstract]   [Full Text] [Related]  

  • 40. Hepatic drug metabolism in cystic fibrosis: recent developments and future directions.
    Kearns GL
    Ann Pharmacother; 1993 Jan; 27(1):74-9. PubMed ID: 8431626
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.